Novai
Paul Stevens has a diverse work experience in various finance and leadership roles. In 1998, they started their career as a Financial Accountant at Schlumberger before moving on to Mondi Packaging, where they held positions as a Financial Accountant, Project Manager, and Finance Director. Paul then worked as an Interim Financial Controller at Oregon Scientific in 2005. From 2006 to 2008, Paul served as the Finance Director at Mabanaft, a UK-based oil distribution and trading company. Paul then joined Aegate as the Head of Finance, responsible for financial management and contributing to the company's strategy. In 2013, Paul co-founded Clinical Insights Ltd, serving as the CFO and playing a crucial role in securing funding, developing systems, and securing subscription sales. Paul later became the Chief Operating Officer at ITR GLOBAL LIMITED, a position they held from 2019 to 2021. Paul then worked as an Associate Director at BCMS before becoming an Interim Finance Director at Wellfound Ltd. Currently, they serve as the Finance Director at Novai, starting in September 2022. Throughout their career, Paul has gained extensive experience in finance, accounting, strategy, and operational efficiency.
Paul Stevens has a Bachelor of Science (BSc Hons) degree in Mathematics from The University of Manchester. Additionally, they have obtained several certifications including Agile Requirements Foundations, Business Analysis Foundations, Business Analysis Foundations: Business Process Modeling, Business Analyst and Project Manager Collaboration, Business Benefits Realization Foundations, Career Essentials in Business Analysis by Microsoft and LinkedIn, Learning Data Science: Understanding the Basics, Managing Data with Microsoft 365, Managing Projects with Microsoft 365, Project Management Foundations: Requirements, Requirements Elicitation and Analysis, Requirements Elicitation for Business Analysts: Interviews, and What Is Business Analysis? from LinkedIn. Paul also holds the Change Management Foundation and Change Management Practitioner certifications from APMG International, and the PRINCE2® Foundation CPD certification from AXELOS. Paul is also a Fellow of the Association of Chartered Certified Accountants (ACCA).
This person is not in any teams
Novai
Novai is a British biotechnology start-up, commercialising DARC Technology, an exploratory retinal biomarker for use in Age-related Macular Degeneration (AMD) & glaucoma clinical studies. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level diseaseactivity. DARC Technology can be used to measure the impact of current and future therapeutics and interventions by assessment of disease activity whilst identifying non-responders to existing and new interventions, resulting in the avoidance of costly, ineffective or un-required medical management. DARC helps to stratify patients in clinical trials, resulting in the creation of enriched patient cohorts, consisting of those at highest risk of rapid disease progression.DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA. Following further analysis of Phase II data, several other indications may follow, including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus and Cancer.